A major mainstream outlet (top-50 US or UK publication by traffic) will publish a feature conflating psilocybin cocaine use disorder trial findings with recreational microdosing trends by July 7, 2026, generating at least one named researcher publicly objecting within 14 days of publication.

A major news organization will publish a feature story that mixes up two completely different things: (1) a clinical trial using psilocybin to treat cocaine addiction through a specific mechanism called extinction learning, and (2) people taking tiny doses of psilocybin recreationally. The outlet will imply they work the same way because both involve psilocybin and 'brain change.' A named researcher will publicly object within two weeks.

This is the most specific operationalization of the media-misrepresentation risk. The cocaine RCT's mechanism — extinction learning augmentation — is technically orthogonal to microdosing's proposed sub-perceptual neuroplasticity effects, but both involve psilocybin and 'brain change,' which is sufficient for conflation. The $2M biohacker cultural context demonstrates that adjacent psilocybin hype is active. Resolution requires: (1) named major outlet, (2) identifiable conflation of cocaine RCT with microdosing, (3) named researcher objection. This is harder to satisfy than the broader media prediction above, hence lower confidence.